Tilray Inc (NASDAQ:TLRY) engages in the research, cultivation, processing, and distribution of medical\u00a0cannabis.<\/p>\n
The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech\u00a0Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is\u00a0headquartered in Nanaimo, Canada.<\/p>\n
We see the company as something approaching a catastrophe for investors in terms of actual\u00a0fundamental model and path analysis. It\u2019s a giant pile of hype and convertible debt. Technically, the stock\u00a0has been racing to the downside for nearly a year after the short-squeeze fever pitch parabolic moved\u00a0topped last fall at exactly $300\/share.<\/p>\n
It has already lost 90% of its value from that point, and the trend continues to point lower following a\u00a0disastrous Q2 report that featured a much larger bottom line loss than expected, with the culprit being the\u00a0worst possible factor: debt-servicing payments on long-term convertible debt. That will likely be hanging\u00a0on the company for years to come.<\/p>\n
International Spirits and Wellness Holdings, Inc (OTCMKTS:ISWH) is a refreshing alternative to\u00a0TLRY because it sits at much cheaper levels\u2026 It\u2019s a sub-penny stock. We normally wouldn\u2019t cover the\u00a0sub-penny plays, but this is interesting.<\/p>\n
The company just posted its first real revenue quarter this week (data for quarter-ended June 30), posting\u00a0solid results with a massive 6,400% sequential quarterly top-line growth number.<\/p>\n
According to the company, that growth came on the back of its new and emerging home healthcare\u00a0segment \u2013 this is a bit of pivot play. But the company has a partnership deal apparently in the works that\u00a0will push its CBD segment onto the stage for coming reports as another growth driver for sales.<\/p>\n
\u201cNow that we are recognizing revenues from our Home Healthcare segment, shareholders will be pleased\u00a0to see robust signals in terms of new top-line growth,\u201d commented Terry Williams, ISWH CEO. \u201cThe\u00a0product mix is very strong looking ahead, with our CBD product lines in place, the Home Healthcare\u00a0segment showing robust tangible growth, and our award-winning spirits segment continuing to represent\u00a0enormous potential.\u201d<\/p>\n
We would also note that the company appeared to hint toward another big q\/q sequential growth\u00a0performance underway in the current quarter, which could spark plenty of interest in shares if the news\u00a0gets around.<\/p>\n
It may be one to watch this week.<\/p>\n
Cronos Group Inc (NASDAQ:CRON) casts itself as an investment firm in the biopharmaceutical space,\u00a0with a strong emphasis on medical marijuana and cannabis-related research and products.<\/p>\n
Shares of the stock have been in correction mode over the past 5 months, but are now beginning to test\u00a0some extremely interesting levels. The zone from $10-13\/share represents potentially important support,\u00a0marking the region that gave rise to the stock\u2019s parabolic advance from November to February, where we\u00a0saw shares push as much as 150% higher in a matter of weeks.<\/p>\n
In short, the company seeks to invest in other companies, either licensed or actively seeking a license, to\u00a0produce medical marijuana pursuant to Canada\u2019s Marijuana for Medical Purposes Regulations (MMPR).<\/p>\n
The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may\u00a0also advance debt as appropriate. It seeks to make minority investments with appropriate governance\u00a0and shareholder rights. The firm seeks board representation consistent with the size of the investment but\u00a0does not need control.<\/p>\n
Even with that news, the action hasn’t really heated up in the stock, with shares moving net sideways\u00a0over the past week after falling over recent months.<\/p>\n
Cronos Group Inc (NASDAQ:CRON) pulled in sales of $6.7M in its last reported quarterly financials,\u00a0representing top line growth of 768.7%. In addition, the company has an extremely strong balance sheet,\u00a0with cash levels far exceeding current liabilities ($2.3B against $0).<\/p>\n","protected":false},"excerpt":{"rendered":"
Tilray Inc (NASDAQ:TLRY) engages in the research, cultivation, processing, and distribution of medical\u00a0cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, […]<\/p>\n","protected":false},"author":6,"featured_media":42158,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[13829,13734,13914],"stock_ticker":[13823,13915,13648,13916],"class_list":["post-42156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-nasdaqcron","tag-nasdaqtlry","tag-otcmktsiswh","stock_ticker-cron","stock_ticker-iswh-otcmkts","stock_ticker-nasdaq","stock_ticker-tlry-nasdaq","entry"],"acf":[],"yoast_head":"\n